FAM72A-D Gene Signature Shows Promise for liver Cancer Prognosis and Immunotherapy
Table of Contents
A newly identified four-gene signature (FAM72A-D) demonstrates meaningful potential as a diagnostic and prognostic biomarker for hepatocellular carcinoma (HCC), the most common type of liver cancer. Research published in Biochemical and Biophysical Reports [Kong W et al.Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer. Biochem Biophys Rep. 2025;DOI:10.1016/j.bbrep.2025.102358] reveals that this signature can effectively stratify patients into high- and low-risk groups, perhaps guiding treatment decisions, particularly in the realm of immunotherapy.
Identifying a Novel Biomarker for HCC
Hepatocellular carcinoma is a challenging cancer to treat, and accurate prognosis and prediction of treatment response are crucial for improving patient outcomes. Current prognostic models often rely on numerous genes, adding complexity to clinical application.This study highlights the FAM72 family of genes – FAM72A, FAM72B, FAM72C, and FAM72D – as key players in HCC development and progression.
The researchers found that elevated expression of these genes was associated with poorer overall survival in HCC patients. Importantly, a simple two-gene signature comprised of FAM72A and FAM72D proved remarkably effective at risk stratification, outperforming ten previously published multi-gene HCC prognostic models while utilizing far fewer genetic markers. Across five independent patient cohorts, the signature demonstrated strong predictive accuracy, with time-dependent Area Under the Curve (AUC) values consistently exceeding 0.63 and a superior concordance index.
FAM72 Expression and the Tumor Microenvironment
Further investigation using single-cell RNA sequencing revealed where these genes are active within the tumor. FAM72B-D were found to be highly expressed in proliferating T cells, suggesting a role in immune cell function. FAM72A expression extended beyond tumor cells, appearing in myeloid cells and endothelial cells, indicating a broader impact on the tumor microenvironment.
This broader impact is significant. High FAM72 expression and associated risk scores correlated with alterations in immune cell infiltration within the tumor. Specifically, the study observed shifts in T-cell subsets and increased expression of immune checkpoints – proteins that can suppress the immune response. These included PDCD1 (programmed cell death protein 1), CD274 (PD-L1), CTLA4 (cytotoxic T-lymphocyte-associated protein 4), HAVCR2 (TIM-3), ICOS, and TIGIT. These findings suggest that the FAM72 signature coudl help identify patients who might benefit from immunotherapy, a treatment approach that aims to unleash the immune system to fight cancer. National Cancer Institute – Immunotherapy
Mechanism of FAM72 Overexpression and Pathway Analysis
The study also investigated how FAM72 genes become overexpressed.Researchers determined that copy-number variation – changes in the number of copies of a gene – was the primary driver, rather than epigenetic modifications like promoter methylation.
Pathway analysis revealed that the high-risk FAM72 signature was linked to key cellular processes involved in cancer progression, including cell-cycle control, DNA repair, and pathways regulated by the MYC oncogene. These connections reinforce the idea that FAM72 plays a role in tumor proliferation and genomic instability – hallmarks of cancer.
Implications for Future Research and Clinical Practice
The authors conclude that the FAM72A-D gene signature represents a promising advancement in HCC diagnosis, prognosis, and treatment planning. The streamlined FAM72 risk score offers a potentially simpler and more effective method for risk stratification compared to existing models.
Key Takeaways:
* The FAM72A-D gene signature is a novel biomarker for hepatocellular carcinoma (HCC).
* A two-gene signature (FAM72A and FAM72D) accurately predicts patient risk and outperforms existing prognostic models.
* FAM72 expression impacts the tumor microenvironment and immune cell infiltration.
* The signature may help identify patients who would benefit from immunotherapy.
* Copy-number variation drives FAM72 overexpression.
Future research will focus on validating these findings in larger, more diverse patient populations and exploring the potential of targeting the FAM72 pathway for therapeutic intervention. The development of a clinical assay based on this signature could substantially improve the management of HCC and ultimately improve patient outcomes.
Worth a look